US Patent 11136309 Metalloenzyme inhibitor compounds
Patent 11136309 was granted and assigned to PhaseBio Pharmaceuticals on October, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+176 characters)
Article
Patent abstract
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Christopher M. Yates0
Sammy R. Shaver0
Steven Sparks0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 27 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111363090
Date of Patent
October 5, 2021
0Patent Application Number
202001170
Date Filed
January 17, 2020
0Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Oct, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 11136309 Metalloenzyme inhibitor compounds
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11136309
Date of patent
October 5, 2021
Patent application number
20200117
Date Filed
January 17, 2020
Find more entities like US Patent 11136309 Metalloenzyme inhibitor compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
